The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma—Letter

Abstract excerpt

We read with interest the recently published paper by Truini and colleagues (1) describing the peculiar in vitro activity of afatinib on non–small cell lung cancer cell lines harboring the EGFR L747-A750>P mutation. \nWe reviewed our patient database and found 6 cases out of 265 with this specific EGFR mutation (2.2%), similar to the prevalence reported in the paper by Truini and colleagues. Here we report two of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Lung Cancer Treatments and Mutations
• Share to Quinazolinone synthesis and applications